echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Jiangsu pharmaceutical company won the anti-influenza "magic drug" Qilu, Beite and other pharmaceutical companies followed closely

    Jiangsu pharmaceutical company won the anti-influenza "magic drug" Qilu, Beite and other pharmaceutical companies followed closely

    • Last Update: 2021-08-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    A few days ago, the official website of the State Food and Drug Administration showed that Borui Pharmaceuticals (Suzhou) was approved to produce generic 4 types of oseltamivir phosphate capsules, which are deemed to have been reviewed
    .
    According to data from Menet.
    com, in 2020, the total sales of oseltamivir phosphate capsules in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will be nearly 15%.
    100 million yuan, of which, there is a nearly 10% increase in physical pharmacies in cities in China
    .

     
    July 30, 2021, the drug approval document pending information is released
     
    Data show that oseltamivir is a specific inhibitor of neuraminidase, which inhibits the action of neuraminidase, can inhibit the mature influenza virus from detaching from the host cell, thereby inhibiting the spread of influenza virus in the human body To play a role in the treatment of influenza
    .
     
    Sales of Oseltamivir Phosphate Capsules at Terminals in Chinese Urban Entity Pharmacies in Recent Years (Unit: RMB 10,000)
    Source: Mi Nei.
    com, China's urban physical pharmacy terminal competition pattern
     
    According to data from Menet.
    com, in 2020, the total sales of oseltamivir phosphate capsules in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will be nearly 15%.
    100 million yuan, of which Yichang East Sunshine Yangtze River Pharmaceutical has the largest market share
    .
    Affected by the new crown epidemic in China's public medical institutions, sales have dropped significantly year-on-year, while in Chinese urban physical pharmacies, there is still a growth of nearly 10%
    .

     
      
    Source: One-click search on Mi Nei.
    com
     
      At present, there are 4 manufacturers with approvals for the production of oseltamivir phosphate capsules: Roche, Yichang Dongyangyang Yangtze Pharmaceutical, Shanghai Zhongxi Sanwei Pharmaceutical, and Borui Pharmaceutical (Suzhou)
    .
    In terms of consistency evaluation, Yichang East Sunshine Yangtze River Pharmaceutical was approved as a supplementary application, and Borui Pharmaceutical (Suzhou) was approved as a generic 4 category, which is regarded as over-evaluated
    .
    In addition, more than 10 companies including Qilu Pharmaceutical (Hainan), Yangzijiang Pharmaceutical Group, CSPC Ouyi Pharmaceutical, and Chengdu Better Pharmaceutical have submitted listing applications for approval
    .
     
      Source: official website of the State Food and Drug Administration, Mi Nei.
    com database
     
      Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
    .
    The above sales are calculated based on the average retail price of the product at the terminal
    .

      A few days ago, the official website of the State Food and Drug Administration showed that Borui Pharmaceuticals (Suzhou) was approved to produce generic 4 types of oseltamivir phosphate capsules, which are deemed to have been reviewed
    .
    According to data from Menet.
    com, in 2020, the total sales of oseltamivir phosphate capsules in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will be nearly 15%.
    100 million yuan, of which, there is a nearly 10% increase in physical pharmacies in cities in China
    .

     
      July 30, 2021, the drug approval document pending information is released
     
      Data show that oseltamivir is a specific inhibitor of neuraminidase, which inhibits the action of neuraminidase, can inhibit the mature influenza virus from detaching from the host cell, thereby inhibiting the spread of influenza virus in the human body To play a role in the treatment of influenza
    .
     
      Sales of Oseltamivir Phosphate Capsules at Terminals in Chinese Urban Entity Pharmacies in Recent Years (Unit: RMB 10,000)
      Source: Mi Nei.
    com, China's urban physical pharmacy terminal competition pattern
     
      According to data from Menet.
    com, in 2020, the total sales of oseltamivir phosphate capsules in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will be nearly 15%.
    100 million yuan, of which Yichang East Sunshine Yangtze River Pharmaceutical has the largest market share
    .
    Affected by the new crown epidemic in China's public medical institutions, sales have dropped significantly year-on-year, while in Chinese urban physical pharmacies, there is still a growth of nearly 10%
    .

     
      
    Source: One-click search on Mi Nei.
    com
     
      At present, there are 4 manufacturers with approvals for the production of oseltamivir phosphate capsules: Roche, Yichang Dongyangyang Yangtze Pharmaceutical, Shanghai Zhongxi Sanwei Pharmaceutical, and Borui Pharmaceutical (Suzhou)
    .
    In terms of consistency evaluation, Yichang East Sunshine Yangtze River Pharmaceutical was approved as a supplementary application, and Borui Pharmaceutical (Suzhou) was approved as a generic 4 category, which is regarded as over-evaluated
    .
    In addition, more than 10 companies including Qilu Pharmaceutical (Hainan), Yangzijiang Pharmaceutical Group, CSPC Ouyi Pharmaceutical, and Chengdu Better Pharmaceutical have submitted listing applications for approval
    .
     
      Source: official website of the State Food and Drug Administration, Mi Nei.
    com database
     
      Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
    .
    The above sales are calculated based on the average retail price of the product at the terminal
    .

      A few days ago, the official website of the State Food and Drug Administration showed that Borui Pharmaceuticals (Suzhou) was approved to produce generic 4 types of oseltamivir phosphate capsules, which are deemed to have been reviewed
    .
    According to data from Menet.
    com, in 2020, the total sales of oseltamivir phosphate capsules in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will be nearly 15%.
    100 million yuan, of which, there is a nearly 10% increase in physical pharmacies in cities in China
    .

     
      July 30, 2021, the drug approval document pending information is released
     
      Data show that oseltamivir is a specific inhibitor of neuraminidase, which inhibits the action of neuraminidase, can inhibit the mature influenza virus from detaching from the host cell, thereby inhibiting the spread of influenza virus in the human body To play a role in the treatment of influenza
    .
     
      Sales of Oseltamivir Phosphate Capsules at Terminals in Chinese Urban Entity Pharmacies in Recent Years (Unit: RMB 10,000)
      Source: Mi Nei.
    com, China's urban physical pharmacy terminal competition pattern
     
      According to data from Menet.
    com, in 2020, the total sales of oseltamivir phosphate capsules in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will be nearly 15%.
    100 million yuan, of which Yichang East Sunshine Yangtze River Pharmaceutical has the largest market share
    .
    Affected by the new crown epidemic in China's public medical institutions, sales have dropped significantly year-on-year, while in Chinese urban physical pharmacies, there is still a growth of nearly 10%
    .

    Hospital hospital hospital pharmacy pharmacy pharmacy
     
      
    Source: One-click search on Mi Nei.
    com
     
      At present, there are 4 manufacturers with approvals for the production of oseltamivir phosphate capsules: Roche, Yichang Dongyangyang Yangtze Pharmaceutical, Shanghai Zhongxi Sanwei Pharmaceutical, and Borui Pharmaceutical (Suzhou)
    .
    In terms of consistency evaluation, Yichang East Sunshine Yangtze River Pharmaceutical was approved as a supplementary application, and Borui Pharmaceutical (Suzhou) was approved as a generic 4 category, which is regarded as over-evaluated
    .
    In addition, more than 10 companies including Qilu Pharmaceutical (Hainan), Yangzijiang Pharmaceutical Group, CSPC Ouyi Pharmaceutical, and Chengdu Better Pharmaceutical have submitted listing applications for approval
    .
    Enterprise business enterprise
     
      Source: official website of the State Food and Drug Administration, Mi Nei.
    com database
     
      Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
    .
    The above sales are calculated based on the average retail price of the product at the terminal
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.